Abstract Details

Title Effect of Extended Interval Dose Natalizumab therapy on CD19+ and CD34+ cell mobilization from bone marrow and JC Viremia.

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 397

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Lana Zhovtis Ryerson, MD, FAAN (Jersey Shore University Medical Center) PRESENTER	Dr. Zhovtis Ryerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Zhovtis Ryerson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.
Maria Chiara Monaco	Maria Chiara Monaco has nothing to disclose.
Ilya Kister, MD, FAAN (NYU School of Medicine)	Dr. Kister has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech-Roche. Dr. Kister has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Kister has received research support from Genentech. The institution of Dr. Kister has received research support from Novartis. Dr. Kister has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
Tamar Bacon	The institution of an immediate family member of Tamar Bacon has received research support from Novartis. The institution of an immediate family member of Tamar Bacon has received research support from Genentech. An immediate family member of Tamar Bacon has received publishing royalties from a publication relating to health care.
	No disclosure on file
Eugene Major, PhD	No disclosure on file

��ɫ��